GO enrichment of DAPs, including BP, CC, and MF. by Caijin Chen (3107787)

Subjects:

GO and KEGG analysis of DEPs. by Huiyang Jia (14444661)

Comparing contactless gait metrics with clinical gait assessments. by Joseph R. Scarpa (3155859)

Prevalence of CSF biomarkers across age. by Sarah J. Neal (20721301)

Optimization of Linear Loading Strategy for Fuel Cell Initiation Based on Gaussian Process Regression Model (Supporting Information) by Jianbin SU (19730371)

Fig 1 - Fusing multisensory signals across channels and time by Swathi Anil (17382903)

Data Sheet 1_Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greate... by Ayman Alhejazi (21092054)

“…Background<p>Multiple myeloma (MM) is a plasma cell malignancy with significant unmet medical needs, particularly in the treatment of relapsed and refractory disease. …”

Mean muscle activation patterns across the gait cycle during walking with mediolateral (ML) forces for <i>A)</i> able-bodied individuals and <i>B)</i> individuals after stroke duri... by Sanne Ettema (18786312)

Mean muscle activation patterns across the gait cycle during walking with anteroposterior (AP) forces for <i>A)</i> able-bodied individuals and <i>B)</i> individuals after stroke d... by Sanne Ettema (18786312)

Mean muscle activation patterns across the gait cycle during walking with Body Weight Support (BWS) for <i>A)</i> able-bodied individuals and <i>B)</i> individuals after stroke dur... by Sanne Ettema (18786312)

Study selection criteria. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

PICOS criteria for the SLR. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

PRISMA flow chart. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

DDC for four anticoagulants from 2019 to 2023. by Wei Luo (80175)

“…The trends in the utilization and expenditure of anticoagulants were examined using linear regression analysis.</p><p>Results</p><p>From 2019 to 2023, the DDDs of rivaroxaban demonstrated a significant annual increase in most hospitals (<i>p</i> < 0.05). …”

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

“…In both group, the DPSI also decreased significantly one month post-treatment compared to before and after treatment (P = 0.040 and P = 0.018, respectively). …”

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

“…In both group, the DPSI also decreased significantly one month post-treatment compared to before and after treatment (P = 0.040 and P = 0.018, respectively). …”

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

“…In both group, the DPSI also decreased significantly one month post-treatment compared to before and after treatment (P = 0.040 and P = 0.018, respectively). …”

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

“…In both group, the DPSI also decreased significantly one month post-treatment compared to before and after treatment (P = 0.040 and P = 0.018, respectively). …”

The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

“…In both group, the DPSI also decreased significantly one month post-treatment compared to before and after treatment (P = 0.040 and P = 0.018, respectively). …”

The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

“…In both group, the DPSI also decreased significantly one month post-treatment compared to before and after treatment (P = 0.040 and P = 0.018, respectively). …”